Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
Authors
Keywords
-
Journal
Biomolecules
Volume 10, Issue 1, Pages 117
Publisher
MDPI AG
Online
2020-01-10
DOI
10.3390/biom10010117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation
- (2019) Bouchra Kitab et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway
- (2019) Ge Liu et al. FASEB JOURNAL
- Acetylation regulates ribonucleotide reductase activity and cancer cell growth
- (2019) Guo Chen et al. Nature Communications
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- Carcinogenesis and Metastasis in Liver: Cell Physiological Basis
- (2019) Anna Rossetto et al. Cancers
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells
- (2018) Chloé Sauzay et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel
- (2018) Anne Monks et al. CANCER RESEARCH
- Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
- (2017) Jae-Kyung Won et al. HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis
- (2017) Bosheng He et al. MEDICINE
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
- (2017) Gonzalo Lopez et al. PLoS One
- A pathology atlas of the human cancer transcriptome
- (2017) Mathias Uhlen et al. SCIENCE
- In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells
- (2017) Tsang-Pai Liu et al. Oncotarget
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- (2016) Daniel J Klionsky et al. Autophagy
- Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein
- (2016) Xia Liu et al. BIOCHEMICAL PHARMACOLOGY
- ATR–CHK1–E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG
- (2016) Chaoju Gong et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Modulation of Autophagy by Sorafenib: Effects on Treatment Response
- (2016) Nestor Prieto-Domínguez et al. Frontiers in Pharmacology
- Recurrence of Hepatocellular Cancer After Resection
- (2015) Parissa Tabrizian et al. ANNALS OF SURGERY
- E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2
- (2015) Zejun Fang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Hepatitis B virus induces RNR-R2 expression via DNA damage response activation
- (2015) Inna Ricardo-Lax et al. JOURNAL OF HEPATOLOGY
- HISAT: a fast spliced aligner with low memory requirements
- (2015) Daehwan Kim et al. NATURE METHODS
- Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
- (2015) Haiquan Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reciprocal regulation of autophagy and dNTP pools in human cancer cells
- (2014) Wei Chen et al. Autophagy
- New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
- (2014) Antoine Galmiche et al. CANCER LETTERS
- High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma
- (2014) Boin Lee et al. Gut and Liver
- Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
- (2014) Y Aye et al. ONCOGENE
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
- (2014) Scott J Dixon et al. eLife
- Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA
- (2013) Jie Gao et al. BIOMATERIALS
- Targeting ribonucleotide reductase for cancer therapy
- (2013) Jimin Shao et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
- (2012) Vincenzo D'Angiolella et al. CELL
- Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
- (2012) Mohammad Aminur Rahman et al. JOURNAL OF CONTROLLED RELEASE
- Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors
- (2012) Xingyu Lin et al. JOURNAL OF MEDICINAL CHEMISTRY
- NCBI GEO: archive for functional genomics data sets—update
- (2012) Tanya Barrett et al. NUCLEIC ACIDS RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer
- (2011) X. Liu et al. CANCER RESEARCH
- Integrative Genomic Identification of Genes on 8p Associated With Hepatocellular Carcinoma Progression and Patient Survival
- (2011) Stephanie Roessler et al. GASTROENTEROLOGY
- Differential expression in RNA-seq: A matter of depth
- (2011) S. Tarazona et al. GENOME RESEARCH
- A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients
- (2010) S. Roessler et al. CANCER RESEARCH
- Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma
- (2010) R. Satow et al. CLINICAL CANCER RESEARCH
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
- (2010) Mark E. Davis et al. NATURE
- p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer
- (2010) NAN-YUNG HSU et al. Oncology Letters
- Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
- (2009) Keqiang Zhang et al. Molecular Cancer
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genome
- (2009) Ben Langmead et al. GENOME BIOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Mapping and quantifying mammalian transcriptomes by RNA-Seq
- (2008) Ali Mortazavi et al. NATURE METHODS
- RNA-Seq: a revolutionary tool for transcriptomics
- (2008) Zhong Wang et al. NATURE REVIEWS GENETICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started